2. 2
Overview
1 in 3 will get cancer – many will not survive
***
Our mission
develop groundbreaking new treatments for those
suffering with cancer
3. 3
Business Model
DISC TARGET HITS LEAD
PRE-
CLIN
IND PHASE 1 PHASE 2 PHASE 3 APP LAUNCH
LEAD
IND
PACKAGE
EARLY
CLINICAL
PRE-
CLINICAL
10-15 YEAR DEVELOPMENT
Value Inflection:
LICENSE IN PARTNER/
EXIT/IPO
4 – 5 YEAR DEVELOPMENT
4. 4
Phase I Value Creation Potential
Phase I
Oncology
Exits
$100m -
>$300m
5. 5 Spanish National Cancer Research Centre
Collaboration with CNIO - June 2013
6. Comprising first-in-class agents protected by composition
of matter patents
6
Pipeline – Targeted Therapeutics
RESEARCH PRE-CLIN IND PHASE ITARGET
MULTIPLE MYELOMA
NSCLC
IBL-202 (PIM/PI3K)
IBL-300s (PIM/PI3K/mTOR)
HAEM MALIGNANCIESIBL-100s (Pan-PIM)
OTHER K-RAS TUMOURS
B-CELL LYMPHOMAS
B-CELL LYMPHOMAS
Secure Partner after
Phase I
Secure Partner at IND
7. 7
PIM Kinase a driver of resistance in AKT/PI3K
1. PIM expression dramatically
elevated by PI3K/AKT pathway
inhibition
2. PIM mediates feedback loop
driving acquired resistance to a
number of treatment modalities.
Underpins rationale for co-
targeting PI3K and PIM;
huge clinical opportunity
8. 8
IBL-300s – Targeting Molecular Subsets in NSCLC(Stage IV)
EGFR TKI ResistantMutant K-RasDe novo PI3k activation
Lung cancer leading cause of cancer death (1.6m ww)
- NSCLC ~80% = $10bn market by 2020
Role for PI3K and PIM co-targeting in NSCLC Rationale for IBL-300s
NSCLC - K-Ras mutated
in 15-30%
Downstream activation
include
PI3K/AKT/mTOR
PIM inhibition shuts
down growth in mutant
K-Ras NSCLC cell lines
NSCLC - EGFR
mutations in ~10% de
novo
Cancer recurs (~12mo)
with ~10% due to PI3K
activation
PIM elevated in EGFR
TKI resistant lines
Squamous cc – PIK3CA/
PTEN mutations ~30%
PIM and PI3K inhibitors
act synergistically in vitro
and in vivo
PIM mediates PI3K/AKT
resistance
9. 9
Research Collaboration Network
Network spanning US, EU, Australia
NSCLC, pancreatic, ovarian, multiple myeloma, DLBCL,
MCL, CLL, neuroblastoma, breast cancer, mechanistic
10. Leadership
Darren
Cunningham
CEO
15 year record
in licensing,
M&A, IP,
fundraising, IR
Amarin, Elan,
PWC
B. Comm, M.
Acc, FCA
Dr. Michael
O’Neill
Director R&D
22 year drug
discovery and
development
Eli Lilly,
Almirall, Merck
BA
Psychology,
PhD
MANAGEMENT ONCOLOGY ADVISORY PANEL
Prof. Josep
Tabernero
Director, Vall
d’Hebron Institute of
Oncology
Led clinical
development of
PI3K pathway
inhibitors
ESMO Executive
Board
Prof. Funda
Meric-Bernstam
Professor of
Surgical Oncology;
and
Chair Department
of Investigational
Cancer
Therapeutics, M.
D. Anderson
Cancer Center
Dr. Martin Page
30+ years
experience in
oncology R&D
Previous VP, Global
Head of Oncology
Res. J&J
Roles with OSI
Pharma, Oxford
Glycosciences, and
Glaxo-Wellcome
11. Incorporated 2012
Headquartered in Dublin, with base in London
2 full time employees
– Internship program, 3 in 2015
– PhD in TCD via Innovation Partnership
6 board members; panel of international scientific
advisors
6 CROs (UK, France, China, India)
>10 research collaborations (US, Ireland, UK,
Germany, Sweden, Australia)
~€2.2m raised to date (EI, VC and privates)
11
Corporate profile